C
우정바이오
215380KOSDAQ자연과학 및 공학 연구개발업50.0 / 100
Reference Date: 2026-04-13
Financial Score13.5 / 40
News Sentiment12.5 / 25
Momentum12.0 / 20
Disclosure12.0 / 15
AI Analysis: PBR is significantly undervalued vs. peers but the high debt ratio poses financial risk. Declined 10.4% over the past month, and news sentiment is neutral.
Company InformationBased on 2025 Annual Report
Business Overview
Ujeong Bio operates in two main business areas: Bio Business and Infection Control Business, offering services such as biological indicator (BI) testing, genetic toxicity evaluation, and SPR analysis. The biotech industry is growing rapidly due to advancements in oncology drugs, immunotherapy, and obesity treatments, supported by government initiatives and increasing demand for pharmaceutical innovation.
Number of Employees
127people
Average Salary
50.0M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 120.074.0Point
PBR
2.33Industry Average 3.825.5Point
Lower than industry avg (good)
ROE
-21.03Industry Average -32.113.5Point
Below industry avg
Debt Ratio
142.65Industry Average 7.520.0Point
19.0x industry avg (risky)
Trend 2023~20250.5 / 10 points
Revenue Growth Rate
0.5 / 3
Avg ▼0.6% (2-year basis)
Operating Profit Growth Rate
0.0 / 3
Avg ▼89.4% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -13.2% (declining, 3yr)
Detailed News Sentiment
1 totalPositive 0Neutral 0Negative 0
- Neutral
Detailed Momentum
52-week position8.0Point
Near 52w high (82%, uptrend)
Current 3,230Won52-week high 3,60552-week low 1,410
1-month return1.0Point
1m -10.40% (falling)
Volume trend3.0Point
Volume flat
Detailed Disclosure
15 totalPositive 1Neutral 14Negative 0
- Neutral[기재정정]주식등의대량보유상황보고서(일반)2026-04-03
- Neutral주식등의대량보유상황보고서(일반)2026-04-03
- Neutral대표이사변경2026-03-31
- Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-31
- Neutral정기주주총회결과2026-03-31